StockNews.AI
EXEL
StockNews.AI
185 days

Exelixis Announces Final Five-Year Follow-up Results from CheckMate -9ER Trial Evaluating CABOMETYX® (cabozantinib) in Combination with Opdivo® (nivolumab) in Patients with Advanced Kidney Cancer at ASCO GU 2025

1. CABOMETYX shows sustained long-term efficacy with Opdivo in advanced RCC. 2. Final results from the CheckMate-9ER trial bolster confidence in EXEL's growth.

2m saved
Insight
Article

FAQ

Why Bullish?

The sustained efficacy data indicates strong product performance, likely enhancing market confidence in EXEL; similar situations where robust trial results led to price increases include the FDA approval of competing renal cancer treatments.

How important is it?

The findings from the CheckMate-9ER trial are crucial for EXEL's positioning in the competitive RCC market, thus potentially impacting investor decisions significantly.

Why Long Term?

Long-term follow-up results suggest enduring market presence; historical successes of drugs maintaining efficacy over time have resulted in sustained appreciation.

Related Companies

OPDIVOSUNITINIB
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced final results from the phase 3 CheckMate -9ER pivotal trial evaluating CABOMETYX® (cabozantinib) in combination with Opdivo® (nivolumab) versus sunitinib for patients with previously untreated advanced renal cell carcinoma (RCC). After more than five years of follow-up, the findings demonstrated that efficacy benefits with CABOMETYX in combination with Opdivo were sustained long term. These results, including subgro.

Related News